232 related articles for article (PubMed ID: 18945356)
1. Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH).
Nitta H; Hauss-Wegrzyniak B; Lehrkamp M; Murillo AE; Gaire F; Farrell M; Walk E; Penault-Llorca F; Kurosumi M; Dietel M; Wang L; Loftus M; Pettay J; Tubbs RR; Grogan TM
Diagn Pathol; 2008 Oct; 3():41. PubMed ID: 18945356
[TBL] [Abstract][Full Text] [Related]
2. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.
Nitta H; Kelly BD; Padilla M; Wick N; Brunhoeber P; Bai I; Singh S; Ranger-Moore J; Bieniarz C; Tsuda H; Grogan TM
Diagn Pathol; 2012 May; 7():60. PubMed ID: 22647525
[TBL] [Abstract][Full Text] [Related]
3. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
4. [Comparison between analysis of HER2 gene and chromosome 17 in breast cancer by dual-probe chromogenic in situ hybridization and fluorescence in situ hybridization].
Bai YF; Ren GP; Wang B; Teng LS; Liu X
Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):161-5. PubMed ID: 20450761
[TBL] [Abstract][Full Text] [Related]
5. Dual-color dual-hapten in situ hybridization (D-DISH) - Comparison with fluorescence in situ hybridization (FISH) for HER2/neu testing in breast cancer.
Gajaria PK; Tambe S; Pai T; Patil A; Desai SB; Shet TM
Indian J Pathol Microbiol; 2020; 63(2):194-199. PubMed ID: 32317514
[TBL] [Abstract][Full Text] [Related]
6. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of reliability of FISH versus brightfield dual-probe in situ hybridization (BDISH) for frontline assessment of HER2 status in breast cancer samples in a community setting: influence of poor tissue preservation.
Schiavon BN; Jasani B; de Brot L; Vassallo J; Damascena A; Cirullo-Neto J; Ivanildo Neves J; Augusto Soares F; Gobbi H; Malagoli Rocha R
Am J Surg Pathol; 2012 Oct; 36(10):1489-96. PubMed ID: 22982892
[TBL] [Abstract][Full Text] [Related]
8. Automated processing of fluorescence in-situ hybridization slides for HER2 testing in breast and gastro-esophageal carcinomas.
Tafe LJ; Allen SF; Steinmetz HB; Dokus BA; Cook LJ; Marotti JD; Tsongalis GJ
Exp Mol Pathol; 2014 Aug; 97(1):116-9. PubMed ID: 24927872
[TBL] [Abstract][Full Text] [Related]
9. Automated brightfield dual-color in situ hybridization for detection of mouse double minute 2 gene amplification in sarcomas.
Zhang W; McElhinny A; Nielsen A; Wang M; Miller M; Singh S; Rueger R; Rubin BP; Wang Z; Tubbs RR; Nagle RB; Roche P; Wu P; Pestic-Dragovich L
Appl Immunohistochem Mol Morphol; 2011 Jan; 19(1):54-61. PubMed ID: 20881839
[TBL] [Abstract][Full Text] [Related]
10. Optimal Scoring of Brightfield Dual-Color In Situ Hybridization for Evaluation of HER2 Amplification in Breast Carcinoma: How Many Cells Are Enough?
Prendeville S; Corrigan MA; Livingstone V; Feeley L; Bennett MW; Browne TJ; O'Connell F
Am J Clin Pathol; 2016 Mar; 145(3):316-22. PubMed ID: 27124913
[TBL] [Abstract][Full Text] [Related]
11. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811
[TBL] [Abstract][Full Text] [Related]
12. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
Akhdar A; Bronsard M; Lemieux R; Geha S
Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
[TBL] [Abstract][Full Text] [Related]
13. Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samples.
Zhu Y; Lu D; Lira ME; Xu Q; Du Y; Xiong J; Mao M; Chung HC; Zheng G
Exp Mol Pathol; 2016 Apr; 100(2):287-93. PubMed ID: 26626802
[TBL] [Abstract][Full Text] [Related]
14. Analysis of HER2 status in breast carcinoma by fully automated HER2 fluorescence in situ hybridization (FISH): comparison of two immunohistochemical tests and manual FISH.
Yoon N; Do IG; Cho EY
APMIS; 2014 Sep; 122(9):755-60. PubMed ID: 24372629
[TBL] [Abstract][Full Text] [Related]
15. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
[TBL] [Abstract][Full Text] [Related]
16. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.
Papouchado BG; Myles J; Lloyd RV; Stoler M; Oliveira AM; Downs-Kelly E; Morey A; Bilous M; Nagle R; Prescott N; Wang L; Dragovich L; McElhinny A; Garcia CF; Ranger-Moore J; Free H; Powell W; Loftus M; Pettay J; Gaire F; Roberts C; Dietel M; Roche P; Grogan T; Tubbs R
Am J Surg Pathol; 2010 Jun; 34(6):767-76. PubMed ID: 20421783
[TBL] [Abstract][Full Text] [Related]
17. Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC.
Brügmann A; Lelkaitis G; Nielsen S; Jensen KG; Jensen V
Appl Immunohistochem Mol Morphol; 2011 May; 19(3):203-11. PubMed ID: 21475037
[TBL] [Abstract][Full Text] [Related]
18. Automated brightfield break-apart in situ hybridization (ba-ISH) application: ALK and MALT1 genes as models.
Nitta H; Zhang W; Kelly BD; Miller M; Pestic-Dragovich L; Bieniarz C; Vasicek TJ; Marafioti T; Rimsza L; Grogan TM
Methods; 2010 Dec; 52(4):352-8. PubMed ID: 20621192
[TBL] [Abstract][Full Text] [Related]
19. Comparative Performance of Breast Cancer Human Epidermal Growth Factor Receptor 2 Fluorescence In Situ Hybridization and Brightfield In Situ Hybridization on College of American Pathologists Proficiency Tests.
Geiersbach KB; Bridge JA; Dolan M; Jennings LJ; Persons DL; Souers RJ; Tsuchiya KD; Vasalos PH; Moncur JT
Arch Pathol Lab Med; 2018 Oct; 142(10):1254-1259. PubMed ID: 29733681
[TBL] [Abstract][Full Text] [Related]
20. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.
Pedersen M; Rasmussen BB
Diagn Mol Pathol; 2009 Jun; 18(2):96-102. PubMed ID: 19430295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
